scholarly journals The analysis of Th2 cell subsets in house dust mite allergic rhinitis patients after sublingual immunotherapy

2019 ◽  
Vol 154 (1) ◽  
pp. 12-16
Author(s):  
Fumie Ihara ◽  
Daiju Sakurai ◽  
Yoshitaka Okamoto
Keyword(s):  
Allergic Rhinitis ◽  
House Dust ◽  
House Dust Mite ◽  
Sublingual Immunotherapy ◽  
Th2 Cell ◽  
Dust Mite

The effects of house dust mite sublingual immunotherapy in patients with allergic rhinitis according to duration

2015 ◽  
Vol 6 (1) ◽  
pp. 82-87 ◽  
Author(s):  
Zhibin Lin ◽  
Qihong Liu ◽  
Tianying Li ◽  
Dong Chen ◽  
Dehua Chen ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
House Dust ◽  
House Dust Mite ◽  
Sublingual Immunotherapy ◽  
Dust Mite

300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis

2016 ◽  
Vol 12 (11) ◽  
pp. 1141-1151 ◽  
Author(s):  
Pascal Demoly ◽  
Yoshitaka Okamoto ◽  
William H. Yang ◽  
Philippe Devillier ◽  
Karl-Christian Bergmann
Keyword(s):  
Allergic Rhinitis ◽  
House Dust ◽  
House Dust Mite ◽  
Sublingual Immunotherapy ◽  
Dust Mite

Sublingual immunotherapy in patients with house dust mite allergic rhinitis: prospective study of clinical outcomes over a two-year period

2016 ◽  
Vol 130 (3) ◽  
pp. 272-277 ◽  
Author(s):  
J Y Soh ◽  
M Thalayasingam ◽  
S Ong ◽  
E X L Loo ◽  
L P Shek ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
House Dust ◽  
House Dust Mite ◽  
Sublingual Immunotherapy ◽  
Nasal Symptom ◽  
Medication Usage ◽  
Dust Mite ◽  
Symptom Scores

AbstractBackground:Sublingual immunotherapy in patients with allergic rhinitis sensitised to house dust mites is safe, but its efficacy is controversial and sublingual immunotherapy withBlomia tropicalishas not yet been studied. This study sought to evaluate the efficacy of sublingual immunotherapy with house dust mite extract in children and adults with house dust mite allergic rhinitis over a period of two years.Methods:A prospective observational study was conducted of children and adults diagnosed with house dust mite allergic rhinitis who were treated with sublingual immunotherapy from 2008 to 2012. Total Nasal Symptom Scores, Mini Rhinoconjunctivitis Quality of Life scores and medication usage scores were assessed prospectively.Results:Thirty-nine patients, comprising 24 children and 15 adults, were studied. Total Nasal Symptom Scores and Mini Rhinoconjunctivitis Quality of Life scores dropped significantly at three months into therapy, and continued to improve. Medication usage scores improved at one year into immunotherapy.Conclusion:Sublingual immunotherapy with house dust mite extracts, includingB tropicalis, is efficacious as a treatment for patients with house dust mite allergic rhinitis.

scholarly journals Dropouts From Sublingual Immunotherapy and the Transition to Subcutaneous Immunotherapy in House Dust Mite-Sensitized Allergic Rhinitis Patients

2022 ◽  
Vol 2 ◽  
Author(s):  
Huan Chen ◽  
Guo-qing Gong ◽  
Mei Ding ◽  
Xiang Dong ◽  
Yuan-li Sun ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Allergic Asthma ◽  
House Dust ◽  
House Dust Mite ◽  
Sublingual Immunotherapy ◽  
Dropout Rates ◽  
Subcutaneous Immunotherapy ◽  
Transition Rates ◽  
Dust Mite

Purpose: Both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are effective in reducing symptoms and medication scores and inducing long-term efficacy in patients with allergic rhinitis (AR). However, SLIT has been associated with poor patient adherence. This study investigates the factors impacting dropout rates from SLIT in house dust mite (HDM)-sensitized AR patients.Methods: A retrospective study was performed to analyze dropout rates and reasons in AR patients receiving Dermatophagoides farinae (Der f) SLIT with a follow-up period of 2 years.Results: A total of 719 HDM-sensitized AR patients received Der f-SLIT. Dropout rates increased with time and most occurred after 1 year of SLIT. By month 24, 654 (91%) patients had discontinued SLIT. The dropout rates by month 24 were 100, 90.1, and 91.1% in children <5 years old, children aged 5–18 years old, and adults ≥ 18 years old, respectively. Combination with allergic asthma and mono- or multi-sensitization to other aeroallergens did not affect the dropout rates. The most common self-reported reasons for dropouts were refusal of continuation, dissatisfaction with the efficacy, transition to SCIT, and adverse effects. Refusal of continuation increased with age, whereas transition to SCIT decreased with age. Ninety-seven cases transitioned from SLIT to SCIT, and the transition rates increased with time. Comorbid allergic asthma did not affect the transition rates. However, multi-sensitization was associated with a slightly higher rate of transition to SCIT. The most common reason for the transition was dissatisfaction with the efficacy (54.6%), which was only reported by patients older than 5 years. For children who began SLIT at younger than 5 years old, the most common reason (81.2%) for transition was age reaching 5 years.Conclusions: HDM-SLIT has a very high dropout rate, which is mainly due to refusal of continuation and dissatisfaction with the efficacy. Transitioning from SLIT to SCIT may help keep these patients on AIT and thus increase adherence and long-term efficacy.

scholarly journals Tinnitus after administration of sublingual immunotherapy

2017 ◽  
Vol 5 ◽  
pp. 2050313X1771315
Author(s):  
Jacob Juel
Keyword(s):  
Allergic Rhinitis ◽  
Abdominal Pain ◽  
Clinical Practice ◽  
Side Effects ◽  
Respiratory Tract ◽  
House Dust ◽  
House Dust Mite ◽  
Clinical Case ◽  
Sublingual Immunotherapy ◽  
Dust Mite

Background/objectives: Sublingual immunotherapy was first described in 1986. Since then, its use has been increased as an alternative to subcutaneously administered immunotherapy in the treatment of allergic rhinitis. The most common side effects are of oropharyngeal and gastrointestinal in nature, for example, itching, swelling, irritation, ulceration of the oropharynx and nausea, abdominal pain, diarrhoea, and vomiting. More severe side effects are dominated by systemic and respiratory tract manifestations. Results: In this clinical case, the author reports a right-sided transient tinnitus lasting for 48 h after administration of sublingual immunotherapy for house dust mite in allergic rhinitis. Conclusions: This case provide important insights for clinical practice, as tinnitus has not been previously reported as a side effect of sublingual immunotherapy with house dust mite allergens.

Sign in / Sign up

Export Citation Format

Share Document